Umoja Biopharma Raises $53M in Series A Financing

Umoja Biopharma

Umoja Biopharma, a Seattle, WA-based biotechnology company pioneering an integrated in vivo immunotherapy platform, completed a $53m Series A financing.

The round was led by MPM Capital and Qiming Venture Partners USA.

The Series A financing will enable the company to advance its platform and therapeutic programs to early clinical development, attract talent and invest in research.

Led by Andy Scharenberg, M.D., co-founder and CEO, and Michael Jensen, M.D., co-founder, Umoja is a pre-clinical stage biotechnology company providing a suite of innovations to re-engineer a patient’s own immune system to attack and destroy both hematologic and solid organ-based tumors with a simplicity and cost that enables widespread implementation. 

The company’s platform incorporates three core components: the VivoVec delivery platform, RACR/CAR payload architecture, and the TumorTag platform. The VivoVec delivery platform acts in vivo to generate a population of cancer fighting cells, VivoCAR T cells, which can be controlled by the RACR/CAR control system using exogenously administered, FDA approved drugs. TumorTag molecules can be used in combination with the VivoCAR T cells to direct cancer-killing T cells to the tumor and the critical supporting cells of the tumor. 



Join the discussion